Latest Us Market Entry News

4DMedical has landed a $10 million strategic investment from Pro Medicus, aimed at accelerating its commercial growth and advancing its CT – VQ™ technology towards FDA clearance in the US.

PainChek Limited has secured a A$7.5 million placement to fuel its international expansion, with US FDA clearance for its adult pain assessment app expected imminently. The company reports strong license growth and a 26% revenue increase year-on-year.

HITIQ Ltd has launched its PROTEQT smart mouthguard for grassroots sports, secured a five-year exclusive global partnership with Shock Doctor, and raised $1.9 million to fund manufacturing and market growth.

Nanoveu Limited has accelerated its commercial and technological momentum with a $3.02 million capital raise, a breakthrough 33% increase in drone flight time using its edge-AI chip, and progress toward a U.S. OTCQB listing.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.

EZZ Life Science Holdings marked a pivotal quarter with the launch of its EZZDAY brand in the US, a significant Southeast Asia distribution agreement, and expanded domestic retail presence, driving a 46% jump in customer receipts.

PainChek Limited has raised A$7.5 million through a strongly supported placement to accelerate its US market entry following anticipated FDA clearance and expand its innovative AI pain assessment technology internationally.

Imricor Medical Systems reported significant regulatory and commercial progress in Q2 CY25, including CE mark approvals and expanded clinical trials, while maintaining a strong cash position.

AnteoTech has signed a binding Term Sheet with US-based Black Diamond Structures to jointly develop and commercialise an advanced battery additive combining their proprietary technologies, targeting improved lithium-ion battery anodes with higher silicon content.

PainChek has completed its final FDA submission for the PainChek Adult App, targeting the US long-term care market with a potential $100 million annual opportunity. A regulatory decision is expected within 75 days, setting the stage for rapid commercialisation.

Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.

Imricor Medical Systems has secured key European regulatory approvals for its second-generation NorthStar system and initiated its commercial launch, while US FDA submissions progress amid some delays.